INFI - Infinity Pharmaceuticals GAAP EPS of -$0.12 revenue of $0.71M

• Infinity Pharmaceuticals press release ( NASDAQ: INFI ): Q3 GAAP EPS of -$0.12.
• Revenue of $0.71M (+65.1% Y/Y).
• At September 30, 2022, Infinity had total cash and cash equivalents of $47.2 million, compared to $80.7 million at December 31, 2021.
• FY Outlook:
• Net Loss: Infinity continues to expect net loss for 2022 to range from $40 million to $50 million.
• Cash and Investments: Infinity continues to expect to end 2022 with a cash and cash equivalents balance ranging from $35 million to $45 million, which provides a cash runway into 2024. Infinity’s financial guidance does not include additional funding or business development activities even as we move toward a strategic partnership on eganelisib which is our goal to announce in the first quarter of 2023.

For further details see: